Future Medicines Comparison Centre
Pick two. Put them head-to-head.
Retatrutide vs CagriSema? Amycretin vs MariTide? Future medicine vs Mounjaro? Choose any two and compare mechanism, route, frequency, evidence, headline trial results, UK status, strengths and important considerations.
We've made this easy and satisfying to compare, but deliberately avoided made-up “92 pace / 89 shooting” medical scores. Where a number appears, it is tied to a named trial. Different trials are not direct head-to-head contests unless stated.
All options at a glance
| Option | Mechanism | Route | Frequency | Headline evidence | UK position |
|---|---|---|---|---|---|
| Retatrutide | GIP + GLP-1 + glucagon receptor agonist | Injection | Once weekly | 28.3% TRIUMPH-1 mean weight loss at 80 weeks, 12 mg efficacy estimand | Not authorised for routine UK use |
| CagriSema | Cagrilintide (amylin) + semaglutide (GLP-1) | Injection | Once weekly | 22.7% REDEFINE 1 mean weight loss at 68 weeks, efficacy estimand | Not routine UK treatment |
| Amycretin / Zenagamtide | Single-molecule GLP-1 + amylin receptor agonist | Oral + injection studied | Formulation-dependent | Phase 3 Obesity development programme now advancing | Not authorised for routine UK use |
| Orforglipron / Foundayo | Small-molecule GLP-1 receptor agonist | Tablet | Once daily | 12.4% ATTAIN-1 mean weight loss at 72 weeks, highest studied dose | MHRA-authorised in the UK on 10 August 2026 |
| MariTide | GLP-1 agonism + GIP receptor antagonism | Injection | Monthly; longer intervals also under study | ~20% Phase 2 mean weight loss at 52 weeks, higher studied regimens | Not authorised for routine UK use |
| Mounjaro | GIP + GLP-1 receptor agonist | Injection | Once weekly | 22.5% SURMOUNT-1 mean weight change at 72 weeks, 15 mg trial dose | Authorised UK medicine; NHS/private access subject to criteria |
| Wegovy | Semaglutide GLP-1 receptor agonist | Injection / oral formulation now also UK-approved | Weekly injection; oral product has separate instructions | 15.2% STEP 5 mean weight change at 104 weeks, semaglutide 2.4 mg | Authorised UK weight-management medicine |
What should actually influence a decision?
Can you use it now?
An authorised medicine with a regulated supply chain has a practical advantage over a future treatment, even when a future trial percentage looks larger.
Does the evidence fit you?
Diabetes status, starting BMI, comorbidities, trial duration and analysis methods affect results.
Will you stick with it?
Weekly injection, monthly injection and daily tablet all create different real-life adherence trade-offs.
Current vs future: don't miss the obvious
Some visitors will be deciding whether to use a treatment available today or wait for something newer. That is why Mounjaro and Wegovy are included as benchmark options in the dropdown.
If your health needs treatment now, a future drug should not automatically delay an appropriate current option. If you're doing well already, there is equally no need to jump treatments simply because a new one arrives.
Direct head-to-head studies matter more than internet scorecards
Retatrutide has a dedicated Phase 3 comparison programme against tirzepatide. CagriSema already has direct-comparison results from REDEFINE 4. Read the CagriSema guide for the dated results and limitations. Direct trials answer more specific questions than comparisons of unrelated study averages; neither establishes the best treatment for every individual.
Shift Says
The most exciting treatment on paper isn't automatically the best treatment in real life. The winner is the option that is safe for you, evidence-based, genuinely available, affordable enough to sustain and effective enough to improve your health.
Use the checker to understand the landscape. Use a qualified clinician to make the treatment decision.
Sources & evidence
Check the underlying guidance directly: